Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”ASH25: Introducing fixed-dose marstacimab as prophylaxis for patients with haemophilia A and B with inhibitors (>12 years and < 75 years).
Phase 3 BASIS trial results presented by Davide Matino at ASH2025 demonstrate safety and efficay data.
Marstacimab, a monoclonal IgG1 antibody targeting tissue factor pathway inhibitor (TFPI), increased thrombin generation and clot formation. In the BASIS trial, weekly subcutaneous (SC) marstacimab at 150 mg (after 300 mg loading dose) proved superior to on-demand treatment:
- Primary endpoint exceeded: Marstacimab reduced annualized bleeding rate (ABR) for treated bleeds to 1.4 vs. 19.8 for on-demand (p<0.0001) — a 93% reduction
- Consistent efficacy across populations: ABR reductions held steady across hemophilia type (A and B), age groups (adolescents and adults), and geographic regions
- Meaningful clinical impact: 57.8% of marstacimab-treated patients achieved zero treated bleeds during follow-up
- Superior secondary endpoints: Significant reductions in joint bleeds, spontaneous bleeds, and target joint bleeding—all critical for long-term musculoskeletal health
Treatment Advantages:
- Fixed weekly SC dosing—no more reactive bypassing agent consumption
- Dramatic reduction in bypassing agent use: ~94% reduction in yearly aPCC and rFVIIa consumption
- Improved quality of life markers: Significant improvements in Haem-A-QoL physical health domain (−25.9 points, p<0.0001) and total score (−13.5 points, p<0.001
Safety Profile:
✔ Well-tolerated across both observational and active treatment phases
✔ No thromboembolic events detected in patients with inhibitors—a critical reassurance for TFPI targeting strategies
✔ Most adverse events mild to moderate; injection site reactions manageable
✔ ADA formation in 10/51 patients (19.6%) had no clinical impact—titers low with natural resolution”
All from ASH25 featured in Hemostasis Today.
-
May 7, 2026, 15:42Chokri Ben Lamine: CVC-Associated UE-DVT and Catheter Removal
-
May 7, 2026, 15:38Samwel Mikaye: Key Insights on Vitamin B12 Deficiency
-
May 7, 2026, 15:37Anika Islam: A ‘Normal’ Hemoglobin Doesn’t Mean Your Patient is Safe for Surgery
-
May 7, 2026, 15:36Ekomobong Sunday: If You are Pregnant and Always Tired, Read This
-
May 7, 2026, 15:35Osama Ramadan: Comprehensive Review – 75 UWorld Anemia and RBC Disorders Questions Solved
-
May 7, 2026, 15:34Eve Barys: What’s New – Thrombosis in Immune Thrombocytopenia
-
May 7, 2026, 15:33Tareq Abadl: The Hidden Danger in a Blood Bag – When a Unit Looks ‘Wrong’
-
May 7, 2026, 15:23Ahmed Nasreldein: Pleasure to Reconnect with Friends and Colleagues from Around the World at ESOC 2026
-
May 7, 2026, 15:14Meta-analysis of RCTs – International Journal of Stroke